II类Eplet错配影响预防供体特异性抗体所需的他克莫司谷浓度
该研究纳入596例肾移植受者,分析50,011次他克莫司谷浓度与HLA-DR/DQ eplet错配的关系。发现HLA-DR/DQ eplet错配和他克莫司谷浓度是dnDSA开发的独立预测因素,高风险受者不应目标谷浓度低于5 ng/ml。
要点
- HLA-DR/DQ eplet错配是他克莫司治疗下dnDSA开发的独立预测因素。
- 高风险受者他克莫司谷浓度低于5 ng/ml时dnDSA风险增加。
- 高风险受者除非必要,不应将他克莫司谷浓度目标设为低于5 ng/ml。
核心结论
- HLA-DR/DQ eplet错配和他克莫司谷浓度是dnDSA开发的独立预测因素。
研究设计与样本
- 回顾性队列研究,纳入596例肾移植受者,共50,011次连续他克莫司谷浓度检测。
- 使用HLAMatchmaker软件确定HLA-DR/DQ eplet错配。
主要发现
- HLA-DR/DQ eplet错配是dnDSA开发的显著多变量预测因素。
- 环孢素方案受者dnDSA发生率比他克莫司方案受者高2.7倍。
- 发生HLA-DR/DQ dnDSA的他克莫司治疗受者中,谷浓度低于5 ng/ml的比例更高,校正HLA-DR/DQ eplet错配后仍显著。
- dnDSA开发前6个月的平均他克莫司谷浓度显著低于同一患者dnDSA开发前6个月以上的水平。
- 高风险HLA eplet错配评分受者更难以耐受低他克莫司水平而不发生dnDSA。
关键数值与推荐
- 他克莫司谷浓度阈值:低于5 ng/ml与dnDSA风险相关。
- 环孢素方案受者dnDSA发生率比他克莫司方案受者高2.7倍。
临床怎么用
- 高HLA同种免疫风险受者除非必要,不应将他克莫司谷浓度目标设为低于5 ng/ml。
- 在此情况下可考虑监测dnDSA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite more than two decades of use, the optimal maintenance dose of tacrolimus for kidney transplant recipients is unknown. We hypothesized that HLA class II de novo donor-specific antibody (dnDSA) development correlates with tacrolimus trough levels and the recipient's individualized alloimmune risk determined by HLA-DR/DQ epitope mismatch. A cohort of 596 renal transplant recipients with 50,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined using HLAMatchmaker software. We analyzed the frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and the mean tacrolimus levels before dnDSA development in the context of HLA-DR/DQ eplet mismatch. HLA-DR/DQ eplet mismatch was a significant multivariate predictor of dnDSA development. Recipients treated with a cyclosporin regimen had a 2.7-fold higher incidence of dnDSA development than recipients on a tacrolimus regimen. Recipients treated with tacrolimus who developed HLA-DR/DQ dnDSA had a higher proportion of tacrolimus trough levels <5 ng/ml, which continued to be significant after adjustment for HLA-DR/DQ eplet mismatch. Mean tacrolimus trough levels in the 6 months before dnDSA development were significantly lower than the levels >6 months before dnDSA development in the same patients. Recipients with a high-risk HLA eplet mismatch score were less likely to tolerate low tacrolimus levels without developing dnDSA. We conclude that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of dnDSA development. Recipients with high HLA alloimmune risk should not target tacrolimus levels <5 ng/ml unless essential, and monitoring for dnDSA may be advisable in this setting.
引用
- Wiebe C, Rush DN, Nevins TE, et al. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. J Am Soc Nephrol. 2017. PMID: 28729289. doi:10.1681/ASN.2017030287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。